Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
出版年份 2020 全文链接
标题
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
作者
关键词
-
出版物
Cancers
Volume 12, Issue 1, Pages 186
出版商
MDPI AG
发表日期
2020-01-13
DOI
10.3390/cancers12010186
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Y6, an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone Resistance
- (2019) Rui-Qiang Zhao et al. Frontiers in Pharmacology
- ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance
- (2019) Xudong Gao et al. OncoTargets and Therapy
- Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells
- (2019) Zhuo-Xun Wu et al. BIOCHEMICAL PHARMACOLOGY
- Capmatinib for the treatment of non-small cell lung cancer
- (2019) Johan Filip Vansteenkiste et al. Expert Review of Anticancer Therapy
- The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model
- (2018) Na Zhan et al. GENE EXPRESSION
- Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
- (2018) Mohamed Bouattour et al. HEPATOLOGY
- Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
- (2018) David E. Gerber et al. LUNG CANCER
- Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
- (2018) Scott M. Jackson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
- (2018) Scott M. Jackson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance
- (2018) Ning Ji et al. BIOCHEMICAL PHARMACOLOGY
- Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
- (2018) Wei Zhang et al. Frontiers in Pharmacology
- VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
- (2018) Ning Ji et al. Frontiers in Pharmacology
- Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer
- (2018) Yun-Kai Zhang et al. CANCER LETTERS
- Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
- (2017) Nicola Personeni et al. Oncotarget
- Inhibiting ABCG2 by Ko143 May Enhance the Efficacy of Irinotecan Treatment in Colon Cancer
- (2015) Hoang Dinh Tuy et al. Clinical Gastroenterology and Hepatology
- Molecular mechanisms of drug resistance and its reversal in cancer
- (2015) Melis Kartal-Yandim et al. CRITICAL REVIEWS IN BIOTECHNOLOGY
- Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
- (2015) Qingfeng Xiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
- (2014) Qingcheng Mao et al. AAPS Journal
- Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter-Mediated Drug Resistance
- (2014) A. Aoyama et al. MOLECULAR CANCER THERAPEUTICS
- GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
- (2013) Lily L. Remsing Rix et al. ACS Chemical Biology
- A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
- (2013) A Santoro et al. BRITISH JOURNAL OF CANCER
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
- (2012) Assunta Sgambato et al. CURRENT PHARMACEUTICAL DESIGN
- Effects of DMSO on gene expression in human and rat hepatocytes
- (2011) Kayo Sumida et al. HUMAN & EXPERIMENTAL TOXICOLOGY
- Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression
- (2011) Takeo Nakanishi et al. Chinese Journal of Cancer
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started